Browsing Tag


April 2017 | Immune to Cancer Blog

On May 1, 2017, the anti-PD-L1 checkpoint immunotherapy durvalumab (IMFINZITM, AstraZeneca) was approved for bladder cancer patients with locally advanced or metastatic disease that progressed after treatment with…

April 2018 | Immune to Cancer Blog

This Saturday, April 14, roughly 20,000 people—including many of the top cancer researchers and clinicians from all over the world—will convene in Chicago to discuss the latest basic, translational, clinical, and…

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.